Fifth Third Bancorp Boosts Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Fifth Third Bancorp lifted its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 49.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 32,805 shares of the company’s stock after purchasing an additional 10,820 shares during the quarter. Fifth Third Bancorp’s holdings in Teva Pharmaceutical Industries were worth $550,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Golden State Wealth Management LLC purchased a new position in Teva Pharmaceutical Industries during the first quarter worth $39,000. New Age Alpha Advisors LLC purchased a new position in Teva Pharmaceutical Industries during the first quarter worth $43,000. Compagnie Lombard Odier SCmA purchased a new position in Teva Pharmaceutical Industries during the first quarter worth $54,000. Banque Cantonale Vaudoise purchased a new position in Teva Pharmaceutical Industries during the first quarter worth $74,000. Finally, Brooklyn Investment Group boosted its stake in Teva Pharmaceutical Industries by 403.4% during the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock worth $77,000 after buying an additional 4,014 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have commented on TEVA. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Finally, The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a “buy” rating and a $24.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $25.14.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $19.17 on Tuesday. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The business has a 50 day moving average price of $17.83 and a 200 day moving average price of $16.72. The stock has a market cap of $21.99 billion, a price-to-earnings ratio of -119.81, a PEG ratio of 1.07 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company had revenue of $4.18 billion during the quarter, compared to analysts’ expectations of $4.34 billion. During the same quarter in the previous year, the business earned $0.61 earnings per share. The firm’s revenue for the quarter was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 52,742 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Placid Jover sold 6,053 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the sale, the insider owned 6,774 shares of the company’s stock, valued at approximately $102,693.84. This represents a 47.19% decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.